Check-Mate 141 Results: Nivolumab Improved OS in Patients With Recurrent or Metastatic Head and Neck Cancer
Not all patients who received nivolumab, however, had improved PFS.
AACR 2018
BLU-667 Promising in RET-Altered Solid Tumors
Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.
Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer
At the time of final analysis, 192 of 302 patients had died.
Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma
Improvement in RFS was seen regardless of PD-L1 status.
Rotavirus Vaccine May Overcome Immunotherapy Resistance
Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.
CTCs May Not Have Genetic Changes Found in Primary Lung Tumors
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Tumor Cell Lysate Vaccine Shows Promise
Antigen-specific T cells increased in frequency in vaccinated mice.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...